<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055000</url>
  </required_header>
  <id_info>
    <org_study_id>170059</org_study_id>
    <secondary_id>17-I-0059</secondary_id>
    <nct_id>NCT03055000</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Mosquitos carry diseases that cause major health problems and death worldwide. The AGS-v&#xD;
      vaccine targets proteins in mosquito saliva. This may help prevent many mosquito-borne&#xD;
      diseases. It might also reduce the lifespan of the mosquito that bites the vaccinated person.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To see if the AGS-v vaccine is safe in humans and how it affects the immune system.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Healthy adults ages 18-50&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened another study.&#xD;
&#xD;
      Participants will be randomly assigned to get either the vaccine with a booster vaccine, the&#xD;
      vaccine without the booster, or a placebo. These are given through a needle in the upper arm.&#xD;
&#xD;
      Participants will have visits that include medical history, physical exam, and blood and&#xD;
      urine tests:&#xD;
&#xD;
      Baseline: They will get the vaccine and be monitored for 2 hours.&#xD;
&#xD;
      Follow-up visits 1 and 2 weeks after baseline.&#xD;
&#xD;
      Visit 3 weeks after baseline: They will get the booster and be monitored for 2 hours.&#xD;
&#xD;
      Follow-up visits 1 and 2 weeks after booster visit.&#xD;
&#xD;
      Visit 3-5 weeks after booster visit: This includes mosquito feeding. Mosquitos grown in the&#xD;
      lab will be allowed to bite the arm. Blood will be drawn 4 times in the 3 hours after the&#xD;
      feeding.&#xD;
&#xD;
      Phone follow-up a few days after the mosquito feeding.&#xD;
&#xD;
      After the feeding visit, 5 follow-up visits about every 2 months&#xD;
&#xD;
      Participants will keep a symptom diary for 7 days after each vaccine. They will record their&#xD;
      temperature. They will measure any redness around the injection site. They will document and&#xD;
      if possible photograph any mosquito bites they get.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mosquito-borne diseases continue to cause significant morbidity and mortality worldwide&#xD;
      despite on-going control efforts. In 2015, there were &gt;200 million cases of malaria&#xD;
      worldwide, causing nearly half a million deaths, with most of the deaths occurring among&#xD;
      children under the age of 5 years. Mosquitos also transmit arboviruses, including dengue,&#xD;
      yellow fever, West Nile virus, chikungunya, Rift Valley fever, Japanese encephalitis, and&#xD;
      Zika virus. The current new outbreak of Zika virus in Central and South America, as well as&#xD;
      the Caribbean, serves as a reminder of how quickly these viruses can spread and how difficult&#xD;
      they can be to control.&#xD;
&#xD;
      In this protocol we plan to perform a Phase I study of a novel universal mosquito-borne&#xD;
      disease vaccine. Through modulation of the immune system after a mosquito feeding, this&#xD;
      vaccine targets the vector saliva and may provide prophylaxis against multiple arboviral and&#xD;
      protozoal diseases. In addition the vaccine potentially leads to a reduced mosquito lifespan&#xD;
      after feeding therefore also reducing transmission of these diseases.&#xD;
&#xD;
      In this protocol we hope to demonstrate the safety of this vaccine similar to SEEK s other&#xD;
      peptide based vaccines Flu-v and HIV-v that have been found to have very good safety profiles&#xD;
      in previous Phase I trials. We also hope to demonstrate immunomodulation after a controlled&#xD;
      clean Aedes aegypti mosquito feeding to demonstrate proof of concept efficacy of the vaccine.&#xD;
      With the current rise of Zika in the Americas and the threat of local mosquito transmission&#xD;
      in the U.S. and the rest of the world, a successful universal mosquito-borne disease vaccine&#xD;
      offers the benefit of targeting this emerging disease as well as the many established&#xD;
      infections such as dengue and malaria that make dealing with this newly emerging epidemic a&#xD;
      challenge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Actual">December 28, 2018</completion_date>
  <primary_completion_date type="Actual">December 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs Grade 3 or Higher</measure>
    <time_frame>1 year after vaccination (study duration)</time_frame>
    <description>Grade 3 or higher adverse events identified within 1 year after 2 vaccinations 21 days apart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GM-CSF Cytokine Level as Measured by Luminex</measure>
    <time_frame>21 days after last vaccination</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-10 Cytokine Level as Measured by Luminex</measure>
    <time_frame>21 days after last vaccination</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-1B Cytokine Level as Measured by Luminex</measure>
    <time_frame>21 days after last vaccination</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-2 Cytokine Level as Measured by Luminex</measure>
    <time_frame>21 days after last vaccination</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-4 Cytokine Level as Measured by Luminex</measure>
    <time_frame>21 days after last vaccination</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-5 Cytokine Level as Measured by Luminex</measure>
    <time_frame>21 days after last vaccination</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interferon-gamma Cytokine Level as Measured by Luminex</measure>
    <time_frame>21 days after last vaccination</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With 1 or More Aes</measure>
    <time_frame>1 year after vaccination (study duration)</time_frame>
    <description>Percent of people with an AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With 1 or More Grade 3 or Higher AE</measure>
    <time_frame>1 year after vaccination (study duration)</time_frame>
    <description>Percent of people with a Grade 3 or higher AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF-a Cytokine Level as Measured by Luminex</measure>
    <time_frame>21 days after last vaccination</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total AGS-v Specific Immunoglobulin</measure>
    <time_frame>21 days after last vaccination</time_frame>
    <description>Total AGS-v specific immunoglobulin measured in serum 14 days after the first and/or second vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GM-CSF Cytokine Level as Measured by Luminex</measure>
    <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-10 Cytokine Level as Measured by Luminex</measure>
    <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1B Cytokine Level as Measured by Luminex</measure>
    <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-2 Cytokine Level as Measured by Luminex</measure>
    <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-4 Cytokine Level as Measured by Luminex</measure>
    <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-5 Cytokine Level as Measured by Luminex</measure>
    <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon-gamma Cytokine Level as Measured by Luminex</measure>
    <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adults Developed From 100 Eggs</measure>
    <time_frame>Day 42 Mosquito feeding</time_frame>
    <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eggs Laid</measure>
    <time_frame>Day 42 Mosquito feeding</time_frame>
    <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Pupae Hatched of 100 Eggs</measure>
    <time_frame>Day 42 Mosquito feeding</time_frame>
    <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Eggs That Developed Into Pupae</measure>
    <time_frame>Day 42 Mosquito feeding</time_frame>
    <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Pupae That Developed Into Adults</measure>
    <time_frame>Day 42 Mosquito feeding</time_frame>
    <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-a Cytokine Level as Measured by Luminex</measure>
    <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
    <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total AGS-v Specific Immunoglobulin</measure>
    <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
    <description>Total AGS-v specific immunoglobulin measured in serum after the first and/or second vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Mosquito-Borne Disease</condition>
  <arm_group>
    <arm_group_label>AGS-v</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGS-v with adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>WFI (0.5mL) on Day 0 and Day 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AGS-v</intervention_name>
    <description>AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21</description>
    <arm_group_label>AGS-v</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AGS-v + adjuvant</intervention_name>
    <description>ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21</description>
    <arm_group_label>AGS-v with adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>WFI (0.5mL) on Day 0 and Day 21</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA:&#xD;
&#xD;
          1. Healthy women and men who are greater than or equal to 18 and less than or equal to 50&#xD;
             years of age.&#xD;
&#xD;
          2. Willingness to complete all study visits and comply with all study requirements.&#xD;
&#xD;
          3. A male subject is eligible for the study if he agrees to practicing abstinence or&#xD;
             using a condom with spermicide plus an acceptable form of contraception (see inclusion&#xD;
             criteria 4) being used by any female partner from 4 weeks before study start to 12&#xD;
             weeks after the second vaccine administration.&#xD;
&#xD;
          4. A female participant is eligible for this study if she is not pregnant or breast&#xD;
             feeding and 1 of the following:&#xD;
&#xD;
               -  Of non-child bearing potential (i.e., women who have had a hysterectomy or tubal&#xD;
                  ligation or are postmenopausal, as defined by no menses in greater than or equal&#xD;
                  to 1 year).&#xD;
&#xD;
               -  Of childbearing potential but agrees to practice effective contraception or&#xD;
                  abstinence for 4 weeks prior to study initiation through 12 weeks after the&#xD;
                  second vaccine administration. Acceptable methods of contraception include a male&#xD;
                  partner who is sterile and is the sole sexual partner of the female participant&#xD;
                  or a male partner who uses a condom with spermicide plus 1 or more of the&#xD;
                  following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an&#xD;
                  intrauterine device with a documented failure rate of &lt;1%; 4) oral&#xD;
                  contraceptives; and 5) double barrier method including diaphragm.&#xD;
&#xD;
          5. Willing to have samples stored for future research (including genetic research).&#xD;
&#xD;
          6. Agrees to abstain from alcohol intake for 24 hours prior to each study visit.&#xD;
&#xD;
          7. Agrees to not donate blood or blood products throughout the study.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Participant has any underlying or current medical condition, which, in the opinion of&#xD;
             the Investigator, would interfere with the participation in the study.&#xD;
&#xD;
          2. Individual with body mass index (BMI) less than or equal to 18 and greater than or&#xD;
             equal to 40.&#xD;
&#xD;
          3. Participants who have a clinically significant (as determined by the PI) baseline&#xD;
             Grade 1 or greater toxicity, or any Grade 3 or greater toxicity (regardless of&#xD;
             clinical significance) by the toxicity table.&#xD;
&#xD;
          4. Receipt of blood or blood products (including immunoglobulins) within 3 months prior&#xD;
             to enrollment.&#xD;
&#xD;
          5. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is&#xD;
             greater) prior to enrollment.&#xD;
&#xD;
          6. Receipt of any unlicensed vaccine within 6 months prior to enrollment.&#xD;
&#xD;
          7. Self-reported or known history of alcoholism or drug abuse within 6 months prior to&#xD;
             enrollment, or positive urine/serum test for drugs of abuse at screening&#xD;
&#xD;
          8. Self-reported or known history of psychiatric or psychological issues that require&#xD;
             treatment and are deemed by the PI to be a contraindication to protocol participation.&#xD;
&#xD;
          9. History of a previous severe allergic reaction with generalized urticaria, angioedema,&#xD;
             anaphylaxis or anaphylactoid reaction.&#xD;
&#xD;
         10. Any condition or event that, in the judgment of the PI, is a contraindication to&#xD;
             protocol participation or impairs the volunteer's ability to give informed consent.&#xD;
&#xD;
         11. Has a known allergy to any of the components of the vaccine.&#xD;
&#xD;
         12. Has a history of severe immunization reaction.&#xD;
&#xD;
         13. Has a severe allergic reaction to mosquito bites&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J Memoli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Peng Z, Yang M, Simons FE. Immunologic mechanisms in mosquito allergy: correlation of skin reactions with specific IgE and IgG antibodies and lymphocyte proliferation response to mosquito antigens. Ann Allergy Asthma Immunol. 1996 Sep;77(3):238-44.</citation>
    <PMID>8814051</PMID>
  </reference>
  <reference>
    <citation>Sidjanski S, Vanderberg JP. Delayed migration of Plasmodium sporozoites from the mosquito bite site to the blood. Am J Trop Med Hyg. 1997 Oct;57(4):426-9.</citation>
    <PMID>9347958</PMID>
  </reference>
  <reference>
    <citation>Ribeiro JM. Role of saliva in blood-feeding by arthropods. Annu Rev Entomol. 1987;32:463-78. Review.</citation>
    <PMID>2880553</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <results_first_submitted>March 5, 2020</results_first_submitted>
  <results_first_submitted_qc>July 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2020</results_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mosquito-Borne Diseases</keyword>
  <keyword>Universal Mosquito Vaccine</keyword>
  <keyword>Mosquito Transmission</keyword>
  <keyword>Vector Borne Viruses</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vector Borne Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03055000/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03055000/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AGS-v</title>
          <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
        </group>
        <group group_id="P2">
          <title>AGS-v With Adjuvant</title>
          <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses givemn 21 days apart</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo 2 doses given 21 days apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AGS-v</title>
          <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
        </group>
        <group group_id="B2">
          <title>AGS-v With Adjuvant</title>
          <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo 2 doses given 21 days apart</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AEs Grade 3 or Higher</title>
        <description>Grade 3 or higher adverse events identified within 1 year after 2 vaccinations 21 days apart.</description>
        <time_frame>1 year after vaccination (study duration)</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>AEs Grade 3 or Higher</title>
          <description>Grade 3 or higher adverse events identified within 1 year after 2 vaccinations 21 days apart.</description>
          <population>All subjects who received vaccination</population>
          <units>adverse events</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" lower_limit="0.16" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.23" upper_limit="0.93"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.22" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GM-CSF Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>21 days after last vaccination</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>GM-CSF Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.106" spread="0.285"/>
                    <measurement group_id="O2" value="3.76" spread="6.05"/>
                    <measurement group_id="O3" value="1.101" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IL-10 Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>21 days after last vaccination</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-10 Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" spread="0.048"/>
                    <measurement group_id="O2" value="1.088" spread="0.169"/>
                    <measurement group_id="O3" value="0.976" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IL-1B Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>21 days after last vaccination</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-1B Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.009" spread="0.119"/>
                    <measurement group_id="O2" value="0.964" spread="0.105"/>
                    <measurement group_id="O3" value="0.946" spread="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IL-2 Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>21 days after last vaccination</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-2 Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.173" spread="0.421"/>
                    <measurement group_id="O2" value="1.225" spread="0.372"/>
                    <measurement group_id="O3" value="1.115" spread="0.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IL-4 Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>21 days after last vaccination</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-4 Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.027"/>
                    <measurement group_id="O2" value="1.018" spread="0.047"/>
                    <measurement group_id="O3" value="0.991" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IL-5 Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>21 days after last vaccination</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-5 Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.267" spread="0.664"/>
                    <measurement group_id="O2" value="4.389" spread="13.32"/>
                    <measurement group_id="O3" value="1.022" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interferon-gamma Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>21 days after last vaccination</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Interferon-gamma Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.568"/>
                    <measurement group_id="O2" value="1.613" spread="0.764"/>
                    <measurement group_id="O3" value="1.103" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With 1 or More Aes</title>
        <description>Percent of people with an AE</description>
        <time_frame>1 year after vaccination (study duration)</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With 1 or More Aes</title>
          <description>Percent of people with an AE</description>
          <population>All subjects who received vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With 1 or More Grade 3 or Higher AE</title>
        <description>Percent of people with a Grade 3 or higher AE</description>
        <time_frame>1 year after vaccination (study duration)</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With 1 or More Grade 3 or Higher AE</title>
          <description>Percent of people with a Grade 3 or higher AE</description>
          <population>All subjects who received vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>TNF-a Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>21 days after last vaccination</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>TNF-a Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.995" spread="0.104"/>
                    <measurement group_id="O2" value="1.255" spread="0.573"/>
                    <measurement group_id="O3" value="0.993" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total AGS-v Specific Immunoglobulin</title>
        <description>Total AGS-v specific immunoglobulin measured in serum 14 days after the first and/or second vaccination.</description>
        <time_frame>21 days after last vaccination</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Total AGS-v Specific Immunoglobulin</title>
          <description>Total AGS-v specific immunoglobulin measured in serum 14 days after the first and/or second vaccination.</description>
          <population>All subjects who received vaccination</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9903" spread="0.373"/>
                    <measurement group_id="O2" value="4.3115" spread="5.08"/>
                    <measurement group_id="O3" value="1.0232" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GM-CSF Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>GM-CSF Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.198" spread="1.289"/>
                    <measurement group_id="O2" value="1.8" spread="5.806"/>
                    <measurement group_id="O3" value="0.902" spread="0.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-10 Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-10 Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.376" spread="2.029"/>
                    <measurement group_id="O2" value="1.749" spread="1.687"/>
                    <measurement group_id="O3" value="0.813" spread="0.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-1B Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-1B Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.905" spread="0.546"/>
                    <measurement group_id="O2" value="0.955" spread="0.281"/>
                    <measurement group_id="O3" value="0.758" spread="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-2 Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-2 Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.027" spread="0.583"/>
                    <measurement group_id="O2" value="1.036" spread="0.138"/>
                    <measurement group_id="O3" value="0.98" spread="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-4 Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-4 Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.034" spread="0.254"/>
                    <measurement group_id="O2" value="1.061" spread="0.157"/>
                    <measurement group_id="O3" value="0.915" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-5 Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>IL-5 Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.233" spread="4.085"/>
                    <measurement group_id="O2" value="3.113" spread="5.993"/>
                    <measurement group_id="O3" value="0.933" spread="0.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interferon-gamma Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Interferon-gamma Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.577" spread="3.954"/>
                    <measurement group_id="O2" value="2.004" spread="4.795"/>
                    <measurement group_id="O3" value="0.594" spread="0.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adults Developed From 100 Eggs</title>
        <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
        <time_frame>Day 42 Mosquito feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adults Developed From 100 Eggs</title>
          <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
          <population>All subjects who received vaccination</population>
          <units>Adult aedes aegypti mosquitoes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.13" spread="14.07"/>
                    <measurement group_id="O2" value="75.25" spread="13.55"/>
                    <measurement group_id="O3" value="78.53" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eggs Laid</title>
        <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
        <time_frame>Day 42 Mosquito feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eggs Laid</title>
          <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
          <population>All subjects who received vaccination</population>
          <units>Eggs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="706" spread="123.75"/>
                    <measurement group_id="O2" value="673.88" spread="221.29"/>
                    <measurement group_id="O3" value="663" spread="165.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Pupae Hatched of 100 Eggs</title>
        <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
        <time_frame>Day 42 Mosquito feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pupae Hatched of 100 Eggs</title>
          <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
          <population>All subjects who received vaccination</population>
          <units>Number of hatched pupae</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.93" spread="13.08"/>
                    <measurement group_id="O2" value="79.62" spread="14.86"/>
                    <measurement group_id="O3" value="81.93" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Eggs That Developed Into Pupae</title>
        <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
        <time_frame>Day 42 Mosquito feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Eggs That Developed Into Pupae</title>
          <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
          <population>All subjects who received vaccination</population>
          <units>percentage of eggs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.59" spread="3.26"/>
                    <measurement group_id="O2" value="15.56" spread="13.58"/>
                    <measurement group_id="O3" value="13.76" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Pupae That Developed Into Adults</title>
        <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
        <time_frame>Day 42 Mosquito feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Pupae That Developed Into Adults</title>
          <description>Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination</description>
          <population>All subjects who received vaccination</population>
          <units>percentage of pupae</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.12" spread="12.8"/>
                    <measurement group_id="O2" value="94.96" spread="6.86"/>
                    <measurement group_id="O3" value="95.77" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TNF-a Cytokine Level as Measured by Luminex</title>
        <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
        <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>TNF-a Cytokine Level as Measured by Luminex</title>
          <description>Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response</description>
          <population>All subjects who received vaccination</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.392" spread="3.464"/>
                    <measurement group_id="O2" value="1.382" spread="5.867"/>
                    <measurement group_id="O3" value="0.707" spread="0.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total AGS-v Specific Immunoglobulin</title>
        <description>Total AGS-v specific immunoglobulin measured in serum after the first and/or second vaccination.</description>
        <time_frame>60 days after Day 42 Mosquito Feeding</time_frame>
        <population>All subjects who received vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>AGS-v</title>
            <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>AGS-v With Adjuvant</title>
            <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo 2 doses given 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Total AGS-v Specific Immunoglobulin</title>
          <description>Total AGS-v specific immunoglobulin measured in serum after the first and/or second vaccination.</description>
          <population>All subjects who received vaccination</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0077" spread="0.29"/>
                    <measurement group_id="O2" value="3.6537" spread="4.45"/>
                    <measurement group_id="O3" value="1.2011" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AGS-v</title>
          <description>825 µg (50 nmol each peptide) non-adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
        </group>
        <group group_id="E2">
          <title>AGS-v With Adjuvant</title>
          <description>825 µg (50 nmol each peptide) adjuvanted AGS-v vaccine 2 doses given 21 days apart</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo 2 doses given 21 days apart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Memoli, Matthew</name_or_title>
      <organization>National Institute of Allergy and Infectious Diseases</organization>
      <phone>+1 301 443 5971</phone>
      <email>mm982v@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

